Bench to bedside: Resuscitation from prolonged ventricular fibrillation

Academic Emergency Medicine

Volumn 8, Issue 9, 2001, Pages 909-924

  Angelos, Mark G ^a,b   Menegazzi, James J ^a,b   Callaway, Clifton W ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Brain; Cardiac arrest; Heart; Resuscitation; Ventricular fibrillation

Indexed keywords

ADRENALIN; ALPHA TOCOPHEROL DERIVATIVE; ANTIARRHYTHMIC AGENT; ANTIOXIDANT; APRIKALIM; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CALPASTATIN; CARIPORIDE; CATALASE; CROMAKALIM; DOBUTAMINE; ESMOLOL; INOTROPIC AGENT; LIDOFLAZINE; MELATONIN; NICORANDIL; PENTOBARBITAL; PHENYLEPHRINE; PINACIDIL; PLACEBO; POTASSIUM CHANNEL STIMULATING AGENT; SUPEROXIDE DISMUTASE; THIOPENTAL;

ACUTE HEART INFARCTION; ANIMAL MODEL; ARTICLE; BRAIN PERFUSION; CLINICAL TRIAL; COMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFIBRILLATION; HEART ARREST; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE METABOLISM; HEART MUSCLE REPERFUSION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HUMAN; HYPOTHERMIA; META ANALYSIS; MULTICENTER STUDY; NEUROLOGICAL COMPLICATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPERFUSION INJURY; RESUSCITATION; STUNNED HEART MUSCLE;

ANIMALS; ELECTRIC COUNTERSHOCK; HUMANS; MYOCARDIUM; REPERFUSION INJURY; RESUSCITATION; VENTRICULAR FIBRILLATION;

EID: 0034842430     PISSN: 10696563     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1553-2712.2001.tb01155.x     Document Type: Article

References (155)

1. The epidemiology of sudden death
2. Cardiac arrest and resuscitation: A tale of 29 cities
3. Predicting survival from out-of-hospital cardiac arrest: A graphic model
4. Guidelines for cardiopulmonary resuscitation. Part 6: Advanced cardiovascular life support, section 2: Defibrillation
5. Transthoracic resistance in human defibrillation: Influence of body weight, chest size, serial shocks, paddle size and paddle contact pressure
6. Factors affecting transthoracic impedance during electrical cardioversion
7. Transthoracic impedance to direct current discharge: Effect of repeated countershocks
8. Prehospital experience with defibrillation of coarse ventricular fibrillation: A ten year review
9. Myocardial uptake of technetium-99m stannous pyrophosphate following direct current transthoracic countershock
10. Cardiac damage produced by direct current countershock applied to the heart
11. Effects of electrical countershock on serum creatine phosphokinase (CPK) isoenzyme activity
12. Metabolic changes and mitochondrial disfunction early following transthoracic countershocks in dogs
13. Myocardial injury from transthoracic defibrillator countershock
14. Death and damage caused by multiple direct current shocks: Studies in animal model
15. The probability of defibrillation success and the incidence of postshock arrhythmia as a function of shock strength
16. Transthoracic ventricular defibrillation in the 100kg calf with symmetrical one-cycle bi-directional rectangular wave stimuli
17. Improved cardiac cell excitation with symmetrical biphasic defibrillator waveforms
18. Comparison of monophasic with single and dual capacitator biphasic waveforms for nonthoracotomy canine internal fibrillation
19. Transthoracic defibrillation of swine with monophasic and biphasic waveforms
20. Comparison of biphasic and monophasic shocks for defibrillation using a non-thoracotomy system
21. Improved low-energy defibrillation efficacy in man with the use of a biphasic truncated exponential waveform
22. A prospective randomized evaluation of biphasic versus monophasic waveform pulses on defibrillation efficacy in humans
23. Comparison of monophasic and biphasic defibrillating pulse waveforms for thransthoracic cardioversion
24. Optimization of biphasic waveforms for human nonthoracotomy defibrillation
25. Dysfunction and safety factor strength-duration curves for biphasic defibrillator waveforms
26. Relation between shock-related myocardial injury and defibrillation efficacy of monophasic and biphasic shocks in a canine model
27. Biphasic transthoracic defibrillation causes fewer ECG ST-segment changes after shock
28. Multicenter comparison of truncated biphasic shocks and standard damped sine wave monophasic shocks for transthoracic ventricular defibrillation
29. Evalutaion of biphasic transthoracic defibrillation in an animal model of prolonged ventricular fibrillation
30. Monophasic versus biphasic transthoracic countershock after prolonged ventricular fibrillation in a swine model
31. Low-energy impedance-compensating biphasic waveforms terminate ventricular fibrillation at high rates in victims of out-of-hospital cardiac arrest
32. A comparison of biphasic and monophasic shocks for external defibrillation
33. Is fibrillation chaos?
34. Spatial and temporal organization during cardiac fibrillation
35. Spatiotemporal evolution of ventricular fibrillation
36. Ventricular fibrillation exhibits dynamical properties and self-similarity
37. Scaling structure of electrocardiographic waveform during prolonged ventricular fibrillation in swine
38. Scaling exponent predicts defibrillation success for out-of-hospital ventricular fibrillation cardiac arrest
39. A novel wavelet transform based analysis reveals hidden structure in ventricular fibrillation
40. "Probability of successful defibrillation" as a monitor during CPR in out-of-hospital cardiac arrested patients
41. American Heart Association report on the Public Access Defibrillation Conference December 8-10, 1994
42. Treatment of prolonged ventricular fibrillation, immediate countershock versus high-dose epinephrine and CPR preceding countershock
43. An experimental algorithm versus standard Advanced Cardiac Life Support in a swine model of out-of-hospital cardiac arrest
44. Combination pharmacotherapy with delayed countershock vs standard Advanced Cardiac Life Support after prolonged ventricular fibrillation
45. Influence of cardiopulmonary resuscitation prior to defibrillation in patients with out-of-hospital ventricular fibrillation
46. Do Advanced Cardiac Life Support drugs increase resuscitation rates from in-hospital cardiac arrest?
47. Association of drug therapy with survival in cardiac arrest-limited role of Advanced Cardiac Life Support drugs
48. A comparison of standard-dose and high-dose epinephrine in cardiac arrest out-side the hospital
49. High-dose epinephrine in adult cardiac arrest
50. A randomized clinical trial of escalating doses of high dose epinephrine during cardiac resuscitation
51. A comparison of repeated high doses of epinephrine for cardiac arrest outside the hospital
52. Effect of cardiac arrest time on cortical cerebral blood flow during subsequent standard external cardiopulmonary resuscitation in rabbits
53. Cardiopulmonary cerebral resuscitation using emergency cardiopulmonary bypass, coronary reperfusion therapy and mild hypothermia in patients with cardiac arrest outside the hospital
54. Cardiac resuscitability with cardiopulmonary bypass after increasing fibrillation time in dogs
55. A preliminary study of cardiopulmonary resuscitation by circumferential compression of the chest with use of a pneumatic vest
56. Phased chest and abdominal compression-decompression. A new option for cardiopulmonary resuscitation
57. Efficacy of interposed abdominal compression-cardiopulmonary resuscitation (CPR), active compression and decompression-CPR and Lifestick CPR: Basic physiology in a spreadsheet model
58. Improving neurologic outcomes after out-of-hospital cardiac arrest
59. Quality of survival after cardiopulmonary resuscitation
60. Medical complications of cardiopulmonary arrest
61. Bacteremia following cardiac arrest and cardiopulmonary resuscitation
62. Prevalence and determinants of acute renal failure following cardiopulmonary resuscitation
63. The stunned myocardium: Prolonged, postischemic ventricular dysfunction
64. Postreperfusion inflammation: A model for reaction to injury in cardiovascular disease
65. Severe neutrophil depletion by leukocyte filters or cytotoxic drug does not improve recovery of contractile function in stunned porcine myocardium
66. Role of neutrophils in myocardial stunning after brief ischaemia: The end of a six year old controversy (1987-1993)
67. Mechanism of myocardial "stunning"
68. Selective effects of oxygen free radicals on excitation-contraction coupling in ventricular muscle
69. Molecular and cellular mechanisms of myocardial stunning
70. Progressive myocardial dysfunction after cardiac resuscitation
71. Myocardial dysfunction after successful resuscitation from cardiac arrest
72. Myocardial dysfunction after resuscitation from cardiac arrest: An example of global myocardial stunning
73. Epinephrine increases the severity of postresuscitation myocardial dysfunction
74. High-energy defibrillation increases the severity of postresuscitation myocardial dysfunction
75. Effects of buffer agents on postresuscitation myocardial dysfunction
76. Combined effects of buffer and adrenergic agents on postresuscitation myocardial function
77. Reversal of dysfunction in postischemic stunned myocardium by epinephrine and postextrasystolic potentiation
78. Recruitment of an inotropic reserve in moderately ischemic myocardium at the expense of metabolic recovery
79. Dobutamine prevents both myocardial stunning an phosphocreatine overshoot without affecting ATP level
80. Postresuscitation left ventricular systolic and diastolic dysfunction. Treatment with dobutamine
81. Regulation of myocardial carbohydrate metabolism under normal and ischemic conditions. Potential for pharmacological interventions
82. In vivo myocardial substrate alteration during perfused ventricular fibrillation
83. Fuels: Aerobic and anaerobic metabolism
84. + channels in isolated guinea pig cardiac myocytes
85. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: An overview of randomized placebo-controlled trials
86. Metabolic modulation of acute myocardial infarction: The ECLA glucose-insulin-potassium pilot trial
87. Low-dose glucose-insulin-potassium is ineffective in acute myocardial infarction: Results of a randomized multicenter Pol-GIK trial
88. Effects of insulin on glucose transport and glucose transporters in rat heart
89. The positive inotropic action of insulin in the canine heart
90. Glucose-insulin-potassium (GIK) improves left ventricular function after global ischemia in the perfused rat heart
91. Glucose, insulin and potassium (GIK) improves myocardial bioenergetic recovery following global ischemia
92. Metabolic intervention for the ischemic and post-ischemic heart
93. Enhancement of recovery of myocardial function by oxygen free-radical scavengers after reversible regional ischemia
94. Beneficial actions of superoxide dismutase and catalase in stunned myocardium of dogs
95. Superoxide dismutase plus catalase improve contractile function in the canine model of the "stunned" myocardium
96. Demonstration of free radical generation in "stunned" myocardium of intact dogs with the use of the spin trap α-phenyl-N-tertbutyl nitrone
97. Demonstration of free radical generation in the "stunned" myocardium in the conscious dog and identification of major differences between conscious an open-chest dogs
98. Effects of combined superoxide dismutase and deferoxamine on recovery of brainstem auditory evoked potentials and EEG after asphyxial cardiac arrest in dogs
99. Melatonin scavenges hydroxyl radical and protects isolated rat hearts from ischemic reperfusion injury
100. Vitamin E analogues reduce the incidence of ventricular fibrillations and scavenge free radicals
101. An alpha-tocopherol analogue with antioxidant activity improves myocardial function during ischemia reperfusion in isolated working rat hearts
102. - channels in cardiac muscle
103. ATP-sensitive potassium channels: A review of their cardioprotective pharmacology
104. Mitochondrial ATP-dependent potassium channels: Novel effectors of cardioprotection?
105. Pharmacological evidence for a role of ATP-dependent potassium channels in myocardial stunning
106. Cardioprotective effects of the potassium channel opener cromakalim: Stereo-selectivity and effects on myocardial adenine nucleotides
107. + channels involves high-energy phosphate preservation
108. ATP-sensitive potassium channels: A review of their cardioprotective pharmacology
109. Effects of intracoronary cromakalim on post-ischaemic contractile function and action potential duration
110. Acidosis during early reperfusion prevents myocardial stunning in perfused hearts
111. + exchange system in the regulation of the internal pH in cultured cardiac cells
112. + exchanger are immediately active upon post-ischemic reperfusion in isolated rat hearts
113. 2+ overload and prolonged acidosis on reperfusion
114. +-overload in ischemia and is cardioprotective
115. Meeting highlights of the 48th Scientific Sessions of the American College of Cardiology
116. GUARD During Ischemia Against Necrosis (GUARDIAN) trial in acute coronary syndromes
117. Cardioprotective effects of the Na(+)/H(+) exchange inhibitor cariporide in patients with acute anterior myocardial infarction undergoing direct PTCA
118. The calcium antagonist nisoldipine improves the functional recovery of reperfused myocardium only when given before ischemia
119. Myocardial stunning: A role for calcium antagonists during ischaemia?
120. Effect of verapamil on post-ischemic "stunned" myocardium: Importance of the timing of treatment
121. Nisoldipine attenuates myocardial stunning induced by multiple coronary occlusions in conscious pigs and this effect is independent of changes in hemodynamics or coronary blood flow
122. Antioxidant effects of calcium channel blockers against free radical injury in endothelial cells. Correlation of protection with preservation of glutathione levels
123. Role of troponin I proteolysis in the pathogenesis of stunned myocardium
124. Protective effect of the protease inhibitor leupeptin against myocardial stunning
125. 2+ responsiveness in stunned rat ventricular myocardium: Relative roles of soluble cytosolic factors versus structural alterations
126. Molecular mechanisms of ischemic neuronal injury
127. Brain bioenergetics during cardiopulmonary resuscitation in dogs
128. Excitotoxic index - A biochemical marker of selective vulnerability
129. Electron spin resonance measure of brain antioxidant activity during ischemia/reperfusion
130. Prolonged hypoperfusion in the cerebral cortex following cardiac arrest and resuscitation in dogs
131. Dynamic heterogeneity of cerebral hypoperfusion after prolonged cardiac arrest in dogs measured by the stable xenon/CT technique: A preliminary study
132. Alteration of transcription factor binding activities in the ischemic rat brain
133. Differential transcription and translation of immediate early genes in the gerbil hippocampus after transient global ischemia
134. Upregulation of bax protein levels in neurons following cerebral ischemia
135. Expression of the apoptosis-effector gene, Bax, is up-regulated in vulnerable hippocampal CA1 neurons following global ischemia
136. Induction of caspase-3-like protease may mediate delayed neuronal death in the hippocampus after transient cerebral ischemia
137. Apoptosis repressor genes Bcl-2 and Bcl-x-long are expressed in the rat brain following global ischemia
138. Release of caspase-9 from mitochondria during neuronal apoptosis and cerebral ischemia
139. Global ischemia can cause DNA fragmentation indicative of apoptosis in rat brain
140. Randomized clinical study of thiopental loading in comatose survivors of cardiac arrest
141. A randomized clinical study of a calcium-entry blocker (lidoflazine) in the treatment of comatose survivors of cardiac arrest
142. Postischemic blockade of AMPA but not NMDA receptors mitigates neuronal damage in the rat brain following transient severe cerebral ischemia
143. Effect of excitatory amino acid receptor blocker MK-801 on overall, neurologic and morphologic outcome after prolonged cardiac arrest in dogs
144. Lack of a neuroprotective effect from N-acetylcysteine after cardiac arrest and resuscitation in a canine model
145. Effect of normoxic ventilation on outcome after asphyxial cardiac arrest in rats
146. A caspase inhibitor blocks ischaemia-induced delayed neuronal death in the gerbil
147. Caspase inhibitors reduce neuronal injury after focal but not global cerebral ischemia in rats
148. Indefatigable CA1 sector neuroprotection with mild hypothermia induced 6 hours after severe forebrain ischemia in rats
149. Delay in cooling negates the beneficial effect of mild resuscitative cerebral hypothermia after cardiac arrest in dogs: A prospective, randomized study
150. Mild protective and resuscitative hypothermia for asphyxial cardiac arrest in rats
151. Effect of mild hypothermia on ischemia-induced release of neurotransmitters and free fatty acids in rat brain
152. Brain temperature alters hydroxyl radical production during cerebral ischemia/reperfusion in rats
153. Hypothermia differentially increases ERK and JNK/SAPK activation in hippocampus after asphyxial cardiac arrest
154. Hypertension with hemodilution prevents multifocal cerebral hypoperfusion after cardiac arrest in dogs
155. Mild resuscitative hypothermia to improve neurological outcome after cardiac arrest. A clinical feasibility trial